Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.85. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | VWO | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | — |
52-Week High | $180.55 | $61.24 |
52-Week Low | $123.10 | $49.54 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
